In order to clarify the pathophysiological roles of renal thromboxane (TX) A
2 in protein excretion and renin release, the urinary excretion and renal synthesis of TXB
2 were assessed in rats with streptozotocin-induced diabetes. Four weeks after the onset of diabetes, marked proteinuria and hyporeninemia were observed together with an approximately 4-fold increase in TXB
2 excretion. However, the renal TXA
2 synthesis was lower than in pre-diabetic controls. Although daily administration of the selective TXA
2 synthesis inhibitor, OKY-046, at 10mg/kg i.p. for 4 weeks after the onset of diabetes did not affect the TXA
2 synthesis and excretion, the urinary excretion of prostaglandin (PG) E
2 and 6-keto-PGF1 y tended to be augmented in association with normalization of the decreased plasma renin activity (PRA), possibly through increased renal renin release. On the other hand, OKY-046 at 100mg/kg i.p, did suppress the renal TXA
2 synthesis together with the urinary excretion of other eicosanoids. The PRA and cortical renin release were again significantly augmented. Microalbuminuria observed in the 4-week diabetic rats tended to decrease upon TXA
2 synthesis blockade. Urinary TXB
2 excretion was positively correlated with proteinuria or albuminuria. However, inhibition of TXA
2 synthesis which was initiated at 4 weeks after the onset of diabetes did not attenuate the proteinuria. These results suggest that renal TXA
2 may be linked with renin release, through either a direct inhibitory action or preserved renal functions upon TXA
2 synthesis blockade, and that it may represent one of the factors responsible for increasing proteinuria, although augmented urinary excretion of TXB
2 may be derived from platelet-borne TXA
2.
抄録全体を表示